Protein C zymogen and methods of use thereof to prevent cancer metastases
AssigneeThe Children's Hospital of Philadelphia
InventorsValder R. Arruda, Katherine A. High, Geerte Van Sluis, Christoffel Arnoldus Spek
Life of this patent
Estimating the term…
Abstract
Compositions and methods useful for the inhibition of cancer metastasis are disclosed.
Claims23
A method for treatment or inhibition of metastasis in a human patient with cancer comprising administration of a therapeutically effective amount of a formulation comprising a human Protein C zymogen variant in a biologically acceptable carrier to the patient, in order to treat said cancer, wherein said cancer in said patient is selected from the group consisting of lung cancer, pancreatic cancer, breast cancer, colon cancer, melanoma and esophageal cancer, wherein said human protein C zymogen variant comprises amino acids 43-461 of SEQ ID NO:2, but for the substitution of the arginine at position 211 in SEQ ID NO:2 by glutamine.
A method for treatment or inhibition of metastasis in a human patient with cancer comprising administration of a therapeutically effective amount of a human protein C zymogen variant in a biologically acceptable carrier to the patient, in order to treat said metastasis, wherein said human protein C zymogen variant is part of a fusion protein, and wherein the human protein C zymogen variant comprises amino acids 43-461 of SEQ ID NO:2, but for the substitution of the arginine at position 211 in SEQ ID NO:2 by glutamine.
A method for treatment or inhibition of metastasis in a human patient with cancer comprising administration of a therapeutically effective amount of a human protein C zymogen variant in a biologically acceptable carrier to the patient, in order to treat said metastasis, wherein said human protein C zymogen variant is pegylated, and wherein the human protein C zymogen variant comprises amino acids 43-461 of SEQ ID NO:2, but for the substitution of the arginine at position 211 in SEQ ID NO:2 by glutamine.
A method for treatment or inhibition of metastasis in a human patient with cancer comprising administration of a therapeutically effective amount of a formulation comprising a human Protein C zymogen variant in a biologically acceptable carrier to the patient, in order to treat said cancer, wherein said cancer in said patient is selected from the group consisting of lung cancer, pancreatic cancer, breast cancer, colon cancer, melanoma and esophageal cancer, wherein said human protein C zymogen variant comprises amino acids 43-461 of SEQ ID NO:2 but for the substitution of the leucine at position 80 in SEQ ID NO:
- 2 by aspartic acid and for the substitution of the arginine at position 211 in SEQ ID NO:2 by glutamine.
A method for treatment or inhibition of metastasis in a patient with cancer comprising administration of a therapeutically effective amount of a human protein C zymogen variant in a biologically acceptable carrier to the patient, in order to treat said metastasis, wherein said human protein C zymogen variant is part of a fusion protein, and wherein said human protein C zymogen variant comprises amino acids 43-461 of SEQ ID NO:2 but for the substitution of the leucine at position 80 in SEQ ID NO:
- 2 by aspartic acid and for the substitution of the arginine at position 211 in SEQ ID NO:2 by glutamine.
A method for treatment or inhibition of metastasis in a patient with cancer comprising administration of a therapeutically effective amount of a human protein C zymogen variant in a biologically acceptable carrier to the patient, in order to treat said metastasis, wherein said human protein C zymogen variant is pegylated, and wherein said human protein C zymogen variant comprises amino acids 43-461 of SEQ ID NO:2 but for the substitution of the leucine at position 80 in SEQ ID NO:
- 2 by aspartic acid and for the substitution of the arginine at position 211 in SEQ ID NO:2 by glutamine.
Dependencies are inferred from the claim text.